Rhumbline Advisers Has $75.34 Million Stock Position in Agilent Technologies, Inc. (NYSE:A)

Rhumbline Advisers lessened its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 7.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 581,199 shares of the medical research company’s stock after selling 46,472 shares during the quarter. Rhumbline Advisers owned approximately 0.20% of Agilent Technologies worth $75,341,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Quantbot Technologies LP bought a new position in Agilent Technologies in the 1st quarter valued at about $938,000. Cetera Investment Advisers increased its stake in shares of Agilent Technologies by 953.3% during the first quarter. Cetera Investment Advisers now owns 32,694 shares of the medical research company’s stock worth $4,757,000 after purchasing an additional 29,590 shares during the period. UBS Group AG lifted its holdings in Agilent Technologies by 84.5% during the 4th quarter. UBS Group AG now owns 325,695 shares of the medical research company’s stock worth $45,281,000 after purchasing an additional 149,159 shares during the last quarter. TD Asset Management Inc boosted its stake in Agilent Technologies by 27.1% in the 4th quarter. TD Asset Management Inc now owns 1,609,420 shares of the medical research company’s stock valued at $223,758,000 after purchasing an additional 343,175 shares during the period. Finally, iA Global Asset Management Inc. grew its holdings in Agilent Technologies by 26.2% in the 1st quarter. iA Global Asset Management Inc. now owns 21,770 shares of the medical research company’s stock valued at $3,168,000 after buying an additional 4,523 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on A shares. JPMorgan Chase & Co. dropped their target price on Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a report on Thursday, May 30th. Wells Fargo & Company assumed coverage on shares of Agilent Technologies in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price objective for the company. TD Cowen increased their target price on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Robert W. Baird lowered their target price on shares of Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating on the stock in a report on Thursday, May 30th. Finally, Citigroup boosted their price target on Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $141.60.

Agilent Technologies Trading Down 0.6 %

A opened at $138.15 on Thursday. The company’s 50 day moving average is $135.32 and its 200-day moving average is $139.01. The company has a market cap of $40.31 billion, a P/E ratio of 32.66, a PEG ratio of 6.63 and a beta of 1.05. Agilent Technologies, Inc. has a 1-year low of $96.80 and a 1-year high of $155.35. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The company’s revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.43 earnings per share. Equities research analysts predict that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the sale, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at $6,595,494.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now owns 24,118 shares in the company, valued at approximately $3,497,110. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Dominique Grau sold 15,000 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the completion of the sale, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The disclosure for this sale can be found here. Insiders sold a total of 18,916 shares of company stock valued at $2,557,230 in the last 90 days.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.